سعر هيوميرا 40مجم/0.4 مل 2 سرنجات معبأة للحقن 2024

Humira (adalimumab) 40 mg/0.4 mL solution for subcutaneous injection, pack of 2 single-dose prefilled syringes, marketed in Egypt by AbbVie Ltd. > Multipharma; TNF-alpha blocking monoclonal antibody.

• Moderately to severely active rheumatoid arthritis in adults (alone or with methotrexate/other non-biologic DMARDs).Population: AdultsDailyMed (U.S. National Library of Medicine)
• Moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years and older.Population: Pediatric patients >=2 yearsDailyMed (U.S. National Library of Medicine)
• Active psoriatic arthritis in adults.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reaction: injection site reactions (erythema and/or itching, hemorrhage, pain or swelling) in 20% vs 14% with placebo, mostly mild. Clinically significant reactions include serious infections, malignancies, hypersensitivity, HBV reactivation, neurologic, hematologic and autoimmune reactions and heart failure.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• The US label lists no contraindications.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - serious infections: increased risk of serious infections leading to hospitalization or death, including active tuberculosis (incl. reactivation), invasive fungal infections and opportunistic bacterial/viral infections; test for latent TB before and during therapy and treat latent TB before starting; discontinue if a serious infection or sepsis develops.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning also covers malignancy; see the label section on malignancies for lymphoma and other malignancies reported with TNF blockers.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hepatitis B virus reactivation (sometimes fatal) may occur in chronic carriers; evaluate patients for HBV infection before starting.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Abatacept, anakinra and other biologic DMARDs or TNF blockersCombination increased serious infections without added benefit in RA; concomitant use is not recommended.DailyMed (U.S. National Library of Medicine)
• Live vaccinesAvoid live vaccines during adalimumab therapy.DailyMed (U.S. National Library of Medicine)

• Available studies do not reliably establish an association between adalimumab and major birth defects (OTIS/MotherToBaby registry: 10% major birth defects with first-trimester use vs 7.5% in a disease-matched cohort, without a pattern); no fetal harm in monkey studies at high exposures.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Present in human milk at 0.1-1% of maternal serum levels; infant systemic exposure expected to be low; no adverse effects on breastfed infants or milk production reported; weigh benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Adalimumab: Binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell-surface TNF receptors; also lyses surface TNF-expressing cells in vitro in the presence of complement; does not bind lymphotoxin (TNF-beta) (US Humira label).